Strategies for implementation and reporting of current CLSI breakpoints and phenotypic confirmatory tests for ESBLs and carbapenemases in gram-negative bacilli in Colombian clinical laboratories;Estrategias para la implementación y reporte de los puntos de corte CLSI vigentes y pruebas fenotípicas confirmatorias para BLEE y carbapenemasas en bacilos Gram negativos en laboratorios clínicos de Colombia

Infectio

Volumn 17, Issue 2, 2013, Pages 80-89

  Esparza, Germán ^a   Ariza, Beatriz ^b   Bedoya, Ana María ^c   Bustos, Ingrid ^d   Castañeda Ramirez, Claudia Rocío ^e   De La Cadena, Elsa ^f   De Arias, María Nilse González ^g   Mónica, Liliana Guerrero ^h   Leal, Aura Lucia ⁱ   Marín, Adriana ^j   Meléndez, Marta Patricia ^k   Rico, Clara Luz ^l   Villegas, María Virginia ^f  

^a PROASECAL SAS   (Colombia)

^b HOSPITAL UNIVERSITARIO SAN IGNACIO   (Colombia)

^c HOSPITAL PABLO TOBÓN URIBE   (Colombia)

^d Fundacion Clinica Shaio   (Colombia)

^e FUNDACIÓN VALLE DEL LILI   (Colombia)

^f CENTRO INTERNACIONAL DE ENTRENAMIENTO E INVESTIGACIONES MÉDICAS CIDEIM   (Colombia)

^g HOSPITAL MILITAR CENTRAL   (Colombia)

^h Fundación Hospital San Pedro   (Colombia)

ⁱ UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^j Laboratorio Clínico   (Colombia)

^k Hospital Central de la Policia   (Colombia)

^l Fundacion Santa Fe   (Colombia)

more..

Author keywords

Breakpoint; Carbapenemases; Cephalosporins; Interpretation; lactamases

Indexed keywords

AZTREONAM; CARBAPENEMASE; CEFAZOLIN; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; MEROPENEM;

ANTIBIOTIC RESISTANCE; ARTICLE; BROTH DILUTION; CLINICAL LABORATORY; DISK DIFFUSION; DRUG DOSE REGIMEN; GOOD LABORATORY PRACTICE; GRAM NEGATIVE BACTERIUM; INFECTION CONTROL; MINIMUM INHIBITORY CONCENTRATION;

EID: 84901740575     PISSN: 01239392     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0123-9392(13)70167-X     Document Type: Article

References (43)

1. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; approved standard. Twenty-second informational supplement. CLSI Document M100-S22. Wayne, PA: CLSI, 2012.
2. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; approved standard. Twelfth informational supplement. CLSI Document M100-S20. Wayne, PA: CLSI, 2010.
3. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial disk susceptibility tests; approved standard. Eleventh edition. CLSI Document M02-A-11. Wayne, PA: CLSI, 2012.
4. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard-ninth edition. CLSI Document M07-A9. Wayne, PA: CLSI, 2011.
5. Clinical and Laboratory Standards Institute (CLSI). Development of in vitro susceptibility testing criteria and quality control parameters; approved guideline-third edition. CLSI Document M23-A3. Wayne, PA: CLSI, 2008.
6. Kahlmeter G. Setting interpretive breakpoints for antimicrobial susceptibility testing using disk diffusion. Int J Antimicrob Agents. 2011;38:281-90
7. Ambrose P, Bhavnani S, Drusano GL. Pharmacokinetics-pharmacodynamics of Antimicrobial Therapy: It's Not Just for Mice Anymore. Clin Infect Dis. 2007;44:79-86
8. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN; for the Antimicrobial Susceptibility Testing Sub-Committee of the Clinical Laboratory Standards Institute. Background and rationale for revised Clinical Laboratory Standards Institute (CLSI) interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: Cephalosporins and aztreonam. Clin Infect Dis. 2013;56:1301-9.
9. Livermore DM, Andrew JM, Hawkey P, Ho PL, Keness Y, Doi Y, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J. Antimicrob Chemoter. 2012;67:1569-77.
10. Organización Panamericana de la Salud. Manual para pruebas de susceptibilidad antimicrobiana. Washington DC: ASM; 2005.
11. Organización Panamericana de la Salud. Guía para el uso correcto de los equipos automatizados para identificación bacteriana y su correspondiente prueba de susceptibilidad. Washington DC: PAHO; 2011.
12. Instituto Nacional de Salud. Proceso Redes en Salud Pública. Prueba de idoneidad en microbiología clínica. PIMC 1-2-2011, 1-2-2010.
13. Gould IM. Antibiotic resistance: understanding how to control it. Int J Antimicrob Agents. 2012;40:193-5.
14. Montealegre MC, Correa A, Briceño DF, Rosas NC, De la Cadena E, Ruiz SJ, et al.; and the Colombian Nosocomial Resistance Study Group. Novel VIM metallo-ß-lactamase variant, VIM-24, from a Klebsiella pneumoniae isolate from Colombia. Antimicrob Agents Chemother. 2011;55:2428-30.
15. Correa A, Montealegre MC, Mojica MF, Maya JJ, Rojas LJ, De la Cadena EP, et al. First report of a Pseudomonas aeruginosa isolate co-harboring KPC and VIM carbapenemases. Antimicrob Agents Chemother. 2012;56:5422-3.
16. Informe Resistencia Bacteriana. Red de Hospitales GREBO 2011.
17. Leal AL, Cortés JA, Arias G, Ovalle MV, Saavedra SY, Buitrago GC, et al. Emergencia de fenotipos resistentes a cefalosporinas de tercera generación en Enterobacteriaceae causantes de infección del tracto urinario de inicio comunitario en hospitales de Colombia. Enferm Infecc Microbiol Clin. 2013;31:298-303.
18. Mojica MF, Correa A, Vargas DA, Maya JJ, Montealegre MC, Rojas LJ, et al. Molecular correlates of the spread of KPCproducing Enterobacteriaceae in Colombia. Int J Antimicrob Agents. 2012;40:277-9.
19. Jorgensen J, Ferraro M. Antimicrobial susceptibility testing: A review of general principles and contemporary practices. Clin Infect Dis. 2009;49:1749-55.
20. Livermore DM. Defining an extended-spectrum beta-lactamase. Clin Microbiol Infect. 2008;14(Suppl. 1):3-10.
21. Turnidge JD. Cefazolin and Enterobacteriaceae: Rationale for revised susceptibility testing breakpoints. Clin Infect Dis. 2011;52:917-24.
22. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22:161-82.
23. Navarro F, Mirelis B. Detección fenotípica de mecanismos de resistencia en microorganismos gramnegativos. Enferm Infecc Microbiol Clin. 2011;29:524-34.
24. Nordqvist K, Zimmer B. Diagnostics as essential tools for containing antibacterial resistance. Drug Resist Updat. 2011;14:95-106.
25. Marchaim D, Sunkara B, Lephart PR, Gudur UM, Bhargava A, Mynatt RP, et al. Extended-spectrum beta-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests. Infect Control Hosp Epidemiol. 2012;33:853-5.
26. Lee NY, Lee CC, Huang WH, Tsui KC, Hsueh PR, Ko WC. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamaseproducing enterobacteriaceae: MIC Matters. Clin Infect Dis. 2013;56:488-95.
27. Rodrigues Baño J, Navarro MD, Retamar P, Pico E, Pascual A, and the Extended-Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria. Beta-lactam/beta-lactamase inhibitor combinations for the treatment of bacteremia due to extended-spectrum betalactamase-producing Escherichia coli: A post hoc analysis of prospective cohorts. Clin Infect Dis. 2012;54:167-74.
28. Nastro M, Piazza LM, Saposnik E, García S, Barberis C, Vay C, et al. Resistencia a cefalosporinas de espectro extendido en enterobacterias sin AmpC inducible. Evaluación de los nuevos puntos de corte. Rev Argent Microbiol. 2012;44:30-5.
29. Nordmann P, Gniadkowski M, Giske CG, Poirel L, Woodford N, Miriagou V, and the European Network on Carbapenemases. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2012;18:432-8.
30. Endimiani A, Perez F, Bajaksouzian S, Windau AR, Good CE, Choudhary Y, et al. Evaluation of updated interpretative criteria for categorizing Klebsiella pneumoniae with reduced carbapenem susceptibility. J Clin Microbiol. 2010;48:4417-25.
31. Landman D, Salamera J, Manisha S, Quale J. Accuracy of carbapenem non susceptibility for identification of KPC-possessing Enterobacteriaceae by use of the revised CLSI breakpoints. J Clin Microbiol. 2011;49:3931-3.
32. Esterly JS, Wagner J, Milena M, McLaughlin MJ, Chao P, Scheetza MH. Evaluation of clinical outcomes in patients with bloodstream infections due to Gram-negative bacteria according to carbapenem MIC stratification. Antimicrob Agents Chemother. 2012;56:4885-90.
33. Viau R, Hujer AM, Marshall SH, Perez F, Hujer KM, Briceño DF, et al. "Silent" dissemination of Klebsiella pneumoniae isolates Bearing K. pneumoniae Carbapenemase in a long-term care facility for children and young adults in Northeast Ohio. Clin Infect Dis. 2012;54:1314-2.
34. Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother. 2012;56:2129-31.
35. Tam VH, Gamez EA, Weston JS, Gerard LN, Larocco MT, Caeiro JP, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis. 2008;46:862-7.
36. Humphries R, Fang F, Aarestrup F, Hindler J. In vitro susceptibility testing of fluoroquinolone activity against Salmonella: Recent changes to CLSI standards. Clin Infect Dis. 2012;55:1107-13.
37. Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 2012;56:2108.
38. Landman D, Georgescu C, Martin DA, Quale J. Polymyxins revisted. Clin Microbiol Rev. 2008;21:449-65.
39. Kwa A, Kasiakou S, Tam VH, Falagas ME. Polymyxin B: Similarities to and differences from colistin (polymyxin E). Expert Rev Anti Infect Ther. 2007;5:811-21.
40. Jenkins SG, Lee J, Patel G, Huprikar S, Calfee D. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol. 2009;47:1611-2.
41. Kelesidis T, Karageorgopoulos E, Kelesidis L, Falagas ME. Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies. J Antimicrob Chemother. 2008;62:895-904.
42. Fernandez F, Curcio D. Tigecycline disk diffusion breakpoints of Acinetobacter spp.: a clinical point of view. J Clin Microbiol. 2007;45:2095.
43. Leal Castro AL, Buitrago GC, Ovalle MV, Cortés JA, Alvarez-Moreno CA, La Rotta J, and the Colombian Tigecycline Susceptibility Surveillance Group. Comparing in vitro activity of tigecycline by using the disk diffusion test, the manual microdilution method, and the VITEK 2 automated system. Rev Argent Microbiol. 2010;42:208-11.